GENETIC ANALYSIS NK -60
Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota; GA-map Dysbiosis Test that detects and characterizes dysbiosis; and GA-map Analyzer, a cloud-based software solution. The company also provides GA-map Discove… Read more
Market Cap & Net Worth: GENETIC ANALYSIS NK -60 (8V8)
GENETIC ANALYSIS NK -60 (F:8V8) has a market capitalization of $2.98 Million (€2.90 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #36350 globally and #4436 in its home market, demonstrating a -2.33% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GENETIC ANALYSIS NK -60's stock price €0.04 by its total outstanding shares 69087041 (69.09 Million).
GENETIC ANALYSIS NK -60 Market Cap History: 2021 to 2026
GENETIC ANALYSIS NK -60's market capitalization history from 2021 to 2026. Data shows change from $42.76 Million to $2.98 Million (-49.94% CAGR).
GENETIC ANALYSIS NK -60 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GENETIC ANALYSIS NK -60's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 8V8 by Market Capitalization
Companies near GENETIC ANALYSIS NK -60 in the global market cap rankings as of March 18, 2026.
Key companies related to GENETIC ANALYSIS NK -60 by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
GENETIC ANALYSIS NK -60 Historical Marketcap From 2021 to 2026
Between 2021 and today, GENETIC ANALYSIS NK -60's market cap moved from $42.76 Million to $ 2.98 Million, with a yearly change of -49.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.98 Million | -1.18% |
| 2025 | €3.01 Million | +88.05% |
| 2024 | €1.60 Million | -57.99% |
| 2023 | €3.82 Million | -67.51% |
| 2022 | €11.74 Million | -72.54% |
| 2021 | €42.76 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of GENETIC ANALYSIS NK -60 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.98 Million USD |
| MoneyControl | $2.98 Million USD |
| MarketWatch | $2.98 Million USD |
| marketcap.company | $2.98 Million USD |
| Reuters | $2.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.